Evidence map›Paper›PMID 39113393›Full record

ArticleJournal of clinical research in pediatric endocrinology2025

Experience in a PTEN Hamartoma Tumor Syndrome Expertise Centre: Yield of Thyroid Ultrasound Surveillance in Children with PTEN Hamartoma Tumor Syndrome

Esther M G Bormans, Janneke H M Schuurs-Hoeijmakers, Petra van Setten, Linda A J Hendricks, Meggie M C M Drissen, Martin Gotthardt, Hedi L Claahsen-van der Grinten, Nicoline Hoogerbrugge, Jolanda H Schieving

Abstract read
In one paragraph

Article in Journal of clinical research in pediatric endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Esther M G BormansAmalia Children’s Hospital, Radboud University Medical Centre, Department of Pediatric Neurology, Nijmegen, The NetherlandsORCID 0009-0005-8568-9648
Janneke H M Schuurs-HoeijmakersRadboud University Medical Centre, Radboud University Medical Centre, Expert Centre for PHTS, Department of Human Genetics, Nijmegen, the NetherlandsORCID 0000-0002-8900-2226
Petra van SettenAmalia Children’s Hospital, Radboud University Medical Centre, Department of Pediatric Endocrinology, Nijmegen, The NetherlandsORCID 0000-0001-5957-9182
Linda A J HendricksRadboud University Medical Centre, Radboud University Medical Centre, Expert Centre for PHTS, Department of Human Genetics, Nijmegen, the NetherlandsORCID 0000-0002-1008-0265
Meggie M C M DrissenRadboud University Medical Centre, Radboud University Medical Centre, Expert Centre for PHTS, Department of Human Genetics, Nijmegen, the NetherlandsORCID 0000-0002-5742-8011
Martin GotthardtRadboud University Medical Center, Department of Medical Imaging and Nuclear Medicine, Nijmegen, The NetherlandsORCID 0000-0002-6537-7744
Hedi L Claahsen-van der GrintenAmalia Children’s Hospital, Radboud University Medical Centre, Department of Pediatric Endocrinology, Nijmegen, The NetherlandsORCID 0000-0003-0181-0403
Nicoline HoogerbruggeRadboud University Medical Centre, Radboud University Medical Centre, Expert Centre for PHTS, Department of Human Genetics, Nijmegen, the NetherlandsORCID 0000-0003-2393-8141
Jolanda H SchievingAmalia Children’s Hospital, Radboud University Medical Centre, Department of Pediatric Neurology, Nijmegen, The NetherlandsORCID 0000-0003-1605-0128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Children with PTEN hamartoma tumor syndrome (PHTS) are at increased risk for developing thyroid abnormalities, including differentiated thyroid carcinoma (DTC). The Dutch PHTS guideline recommends ultrasound surveillance starting from age 18 years. Since the literature describes PHTS patients who developed DTC before this age, the Dutch PHTS expertise center has initiated annual ultrasound surveillance starting from age 12 years. The purpose of this study was to identify the yield of thyroid ultrasound surveillance using this cut-off. Methods: A retrospective, single center, cohort study was conducted. Pediatric PHTS patients who received thyroid ultrasound surveillance before age 18 years between 2016-2023 were included. Medical records were reviewed. Primary outcomes included prevalence and time to develop thyroid nodules ≥10 mm, nodular growth, goiter, thyroiditis and DTC. Descriptive statistics and Kaplan-Meier analyses were performed. Results: Forty-three patients were included. Two (5%) were diagnosed with DTC at ages 12 and 17 years. Both DTCs were identified as minimally invasive follicular carcinoma at stages pT3NxMx and pT1NxMx respectively. A total of 84% were diagnosed with thyroid abnormalities at a median age of 12 (9-18) years. Most common findings were benign, including nodular disease (74%), goiter (30%) and autoimmune thyroiditis (12%). Nodular growth was observed in 14 patients (33%) resulting in (hemi)thyroidectomy in 7 (16%). Conclusion: Thyroid ultrasound surveillance resulted in the detection of DTC in 2/43 (4.65%) PHTS patients before age 18. These findings support the recommendation to initiate thyroid ultrasound surveillance in children with PHTS from at least age 12, preferably within an expertise center.

Indexed as

Hamartoma Syndrome, MultipleThyroid GlandThyroid NeoplasmsAdolescentChildFemaleHumansMaleNetherlandsPTEN PhosphohydrolaseRetrospective StudiesThyroid NoduleUltrasonographyPTEN PhosphohydrolasePTEN protein, humanchildrenCowden syndromedifferentiated thyroid carcinomagoiterPTEN hamartoma tumor syndromethyroid nodulesthyroid ultrasound surveillance

Identifiers

PMID39113393
PMCPMC11923529

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.